We expect that alterations in any of these three module components would disrupt the tumor-suppressive activity of TP53. Though the relationship of MDM2 and TP53 was central to one of the GBM pathways reported by the TCGA Consortium, the link between EP300 dysregulation and the TP53 pathway has not been previously reported in glioblastoma. This evidence concerns the gene EP300 and neoplasm.